Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
24.36
-1.04 (-4.09%)
At close: Jul 15, 2025, 4:00 PM
24.28
-0.08 (-0.33%)
Pre-market: Jul 16, 2025, 4:42 AM EDT
Summit Therapeutics Employees
Summit Therapeutics had 159 employees as of December 31, 2024. The number of employees increased by 54 or 51.43% compared to the previous year.
Employees
159
Change (1Y)
54
Growth (1Y)
51.43%
Revenue / Employee
n/a
Profits / Employee
-$1,514,182
Market Cap
18.09B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 159 | 54 | 51.43% |
Dec 31, 2023 | 105 | 28 | 36.36% |
Dec 31, 2022 | 77 | -33 | -30.00% |
Dec 31, 2021 | 110 | 29 | 35.80% |
Dec 31, 2020 | 81 | 11 | 15.71% |
Dec 31, 2019 | 70 | 9 | 14.75% |
Dec 31, 2018 | 61 | -15 | -19.74% |
Dec 31, 2017 | 76 | 36 | 90.00% |
Dec 31, 2016 | 40 | 3 | 8.11% |
Dec 31, 2015 | 37 | 14 | 60.87% |
Dec 31, 2014 | 23 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
SMMT News
- 1 day ago - SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm - Business Wire
- 11 days ago - Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain - Seeking Alpha
- 15 days ago - Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors - Business Wire
- 5 weeks ago - Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference - Business Wire
- 6 weeks ago - Summit Therapeutics: Market Overreaction Creates Opportunity - Seeking Alpha
- 6 weeks ago - Is SMMT Stock A Buy After Its Recent Plunge? - Forbes
- 6 weeks ago - Summit Therapeutics: Moving Stock To 'Hold' Rating After Phase 3 HARMONi Data Release - Seeking Alpha